RxDoctor Payments Data

Corrin Rodriguez

Psychiatric/Mental Health · Lancaster, OHNPI 1861150617

Payments from drug & device makers

$2,620in general payments, 2019–2025

Across 134 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$615
  • Axsome Therapeutics, Inc.$468
  • Otsuka America Pharmaceutical, Inc.$388
  • Johnson & Johnson$179
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$175
  • Teva Pharmaceuticals USA, Inc.$170
  • plus $625 from 9 others

What the payments were for

  • Food & beverage$2,620100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,620 in reported general payments places this provider in the 80th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$97,115
Medicare patients
131
Services billed
1,198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl58$90,065
AustedoDeutetrabenazine14$83,053
SpravatoEsketamine Hcl28$42,263
Lurasidone Hcl67$37,892
RexultiBrexpiprazole27$37,721
NuedextaDextromethorphan Hbr/Quinidine12$9,279
Aripiprazole70$8,390
VyvanseLisdexamfetamine Dimesylate17$7,260
TrintellixVortioxetine Hydrobromide11$5,449
Paliperidone ErPaliperidone16$3,579
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine147$3,502
Oxcarbazepine62$3,346
Bupropion XlBupropion Hcl146$3,127
Divalproex Sodium25$2,539
Alprazolam312$1,953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$615$90,06558 claims
Teva Pharmaceuticals USA, Inc.Austedo$170$83,05314 claims
Johnson & JohnsonSpravato$179$42,26328 claims
Otsuka America Pharmaceutical, Inc.Rexulti$388$37,72127 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix$76$12,70928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Lancaster

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →